Abstract
The lungs are considered by many to be the best alternative for drugs needing
to bypass the gastrointestinal tract. With advancing technology, the practice
of utilizing the huge surface area of the lungs to delivery drugs into the
blood circulation has been slowly transforming into reality.
The pulmonary drug delivery market reached $25.5 billion in 2006 and is
expected to experience high steady growth in the next five years. Contributing
to growth are new technologies such as dry powder inhalers and new product
offerings that require advanced drug delivery. Pulmonary drug delivery offers
the potential for noninvasive administration of a wide variety of
macromolecules. Nearly every biotherapeutic product that treats chronic or
long-term illness would benefit from noninvasive delivery by providing a
competitive advantage with current therapeutics. This advantage could expand
the market for each product or enable new indications to be considered.
Kalorama' s Drug Delivery Markets. Edition 2 Volume III: Pulmonary Delivery
Systems, the third volume of Kalorama' s popular series focusing on global drug
delivery systems markets, provides the definitive break down of the market for
pulmonary delivery system markets. The report covers both pharmaceuticals sold
through pulmonary delivery systems and the technologies themselves
The report provides current market size and revenue for the following main
categories:
- Inhalation drug delivery
- Intranasal drug delivery
Kalorama believes the future of drug administration by inhalation will expand
vastly and be a significant driver in this market. Serious market-watchers who
are looking at new products or ways to expand existing products will find this
information essential.
As part of its comprehensive cooverage, Kalorama' s report includes:
- A Breakdown of Demographics and Trends that will drive pulmonary
delivery.
- New Developments including Prodrug Technology, Electrohydrodynamic
Aerosol Delivery, Oxygen Delivery and Crystallization Technology
- Detailed Discussion of Current Products in pulmonary drug delivery.
- Current Market Size and Forecasts to 2010.
- Review of Pipleline products
- Profiles of Key Companies in the Pulmonary Delivery markets.
As part of Kalorama' s trusted information-gathering process, industry
executives are consulted. While government and company data is culled, it is
interviews with executives that provide the foundation for market sizes and
forecasts.
Kalorama' s coverage of the pulmonary drug delivery market includes coverage of
the following companies in this field:
- 3M
- Alkermes
- Aradigm
- Elan
- Nastech
- Nektar
- SkyePharma
| 
View Cart
